1. Backgrounds {#sec0005}
==============

The deadly coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2, formerly 2019-nCoV), has emerged in Wuhan, China, in December 2019 ([@bib0005]). COVID-19 cases were soon exported to other Chinese cities and overseas, mainly owing to the traffic surge near the Chinese Lunar New Year ([@bib0010], [@bib0015]). The first imported cases in Hong Kong were confirmed and reported on January 23, 2020, see [Fig. 1](#fig0005){ref-type="fig"}(a). Since then, the government of Hong Kong has implemented a series of control and prevention measures for COVID-19, including enhanced border screening and traffic restrictions ([@bib0020], [@bib0025]). The official news related to the COVID-19 outbreak was first released by the CHP on December 31, 2019. Outbreak-related news reports have been released daily since January 2 and updated at least twice per day since January 23, 2020 ([@bib0025]). After the first week of February, COVID-19 was controlled at 1 incidence onset from February 9 to the present (as of February 15), 2020.Fig. 1The daily SARS-CoV-2 cases time series in (a), and count of tested cases (b) and the association between detection delay (*τ*) and time in (c). Panel (a) shows the time series of the daily number of SARS-CoV-2 cases aggregated by the date of onset (grey horizontal bars) and by the laboratory-confirmed date (black vertical bars). Panel (b) shows the time series of the daily number of tested cases. Panel (c) shows the detection delays (*τ*) of the cases who are Hong Kong residence (blue dots) and of the cases who are not Hong Kong residence (red triangles) vary over the calendar date. The bold curves are the fitting results of the regression in Eqn (1), and the dashed curves are the 95% confidence interval (95%CI).Fig. 1

In this study, we quantify the improving rate of detection efficiency of SARS-CoV-2 in Hong Kong.

2. Data and methods {#sec0010}
===================

The follow-up data of individual patients were collected via the official website of the Centre for Health Protection (CHP) of Hong Kong ([@bib0020]). All cases were laboratory-confirmed following the case definition, referring to the official diagnostic protocol released by WHO ([@bib0030]).

The case detection efficiency is the reciprocal of detection delay, denoted by *τ*. The detection delay (*τ*) is measured by the time interval between the date of COVID-19 symptoms onset and the date of laboratory confirmation. For the *i*-th patient, the detection delay is denoted by *τ* ~*i*,*t*~, where *t* denotes symptoms onset on the *t*-th day. Thus, the time evolution of the detection delay is formulated by a regression model in Eqn (1).$$\mathbf{E}\left\lbrack {\log\left( \tau_{i,t} \right)} \right\rbrack = \beta \cdot t + \beta_{1} \cdot \log\left( {< n >}_{t,t + \tau} \right) + \beta_{2} \cdot \text{isHK}_{i} + \beta_{0}\text{,}$$

where **E**\[·\] represents the expectation. The 'isHK~*i*~' is an indicator that is 1 if the *i*-th patient is a Hong Kong resident but 0 otherwise. The ${\langle n\rangle}_{t,t + \tau}$ denotes the average number of cases being tested between the *t*-th and (*t*  +  *τ*)-th days, and thus it accounts for the effect of time-varying working load. The *β* is the regression coefficient for the onset time variable *t*. The *β* quantifies the rate of change in the detection delay. Since a shorter detection delay means a higher detection efficiency, we expect a negative estimate of *β* for an improving detection efficiency over time. The \[exp(− *β*) − 1\] × 100% quantifies the percentage improvement in the detection efficiency per day in Hong Kong. We fit the model by a Gamma-distributed likelihood framework. The 95% confidence interval (95%CI) of *β* is calculated by using its mean estimate plus and minus its standard deviation (SD) multiplied by the Student\'s *t* quantile.

Validation analysis is conducted by using the Cox proportional hazard (PH) model defined as $S(\tau) = S_{0}(\tau) \cdot \exp\left\lbrack {\alpha \cdot t + \alpha_{1} \cdot \log\left( {\langle n\rangle}_{t,t + \tau} \right) + \alpha_{2} \cdot \text{isHK} + \alpha_{0}} \right\rbrack$, which has a similar form as Eqn (1). The *S*(·) is the survival function, and the *S* ~0~(·) is the baseline survival function. Similarly, the *α* is the regression coefficient for *t* in the hazard function, and thus exp(*α*) is the hazard ratio (HR). In contrast to *β*, we expect a positive estimate of *α* for an improving detection efficiency over time. For validation, we exam the signs of the estimated *α* and *β*, and their statistical significance levels.

3. Results and discussion {#sec0015}
=========================

[Fig. 1](#fig0005){ref-type="fig"}(a) shows the epidemic curve of all 56 COVID-19 cases as of February 15, 2020, in Hong Kong. We reported that the onset cases peaked on January 30, and the confirmed cases peaked on February 9, 2020. The daily number of tests started increasing rapidly from January 23 until the end of January, see [Fig. 1](#fig0005){ref-type="fig"}(b). The estimated median detection delay was 9.5 days (95%CI: 6.5 − 11.5) in the second half of January, and this number was reduced to 6.0 days (95%CI: 5.5 − 9.5) in the first half of February 2020. These estimates indicate the enhancement of infection screening and public interventions for the prevention and control of SARS-CoV-2.

The fitting results of Eqn (1) are shown in [Fig. 1](#fig0005){ref-type="fig"}(c); and the Nagelkerke\'s pseudo-R-squared is 0.38. The non-resident cases are likely to be detected earlier than the resident cases even though there were only 5 non-Hong Kong resident cases. We estimate that SARS-CoV-2 detection efficiency improves 5.40% per day (95%CI: 2.54 − 8.33) in Hong Kong. The estimates of *α* and *β* are consistent in signs, i.e., *α* is positive, and *β* is negative, and statistical significance levels, i.e., both are significant with *p*-values \< 0.05, which validate our estimates. Therefore, we report that the SARS-CoV-2 infection detection efficiency was likely being improved substantially and significantly since January 23, 2020, when the first imported case was detected in Hong Kong.

Due to the unavailability of data, our findings are restricted to the early phase of the COVID-19 outbreak in Hong Kong. However, our analytical approach can be extended to a more complex context. In [Table 1](#tbl0005){ref-type="table"} , the events and control measures during the early outbreak are summarized. Most of the control measures aimed at strengthening the testing efforts, i.e., number of tests and testing efficiency, and reducing the size of the outbreak. Though the control measures would partially affect the testing efforts, we have accounted for these effects by adjusting the ${\langle n\rangle}_{t,t + \tau}$ term in the models. Hence, our estimates should quantify the temporal improvement in detection efficiency.Table 1Summary of the events and control measures during the early phase of the COVID-19 outbreak in Hong Kong (HK).Table 1Date or periodEvent typeDetailsJanuary 17 -control measureTemperature check of all inbound travellers at bordersJanuary 19FactFirst COVID-19 case in HK symptom onsetJanuary 21 -control measureCOVID-19 reporting system in operationJanuary 24 -control measureTesting for all suspected, confirmed cases and close contacts Isolation and quarantineJanuary 25 -control measureActivate the 'Emergency' level of response plan against the outbreakJanuary 23 -fact and control measureLocal schools' holiday, and school closureJanuary 25 - January 28FactChinese lunar new year holidayJanuary 26 -control measureCancellation of major gathering events, and closure of parksJanuary 27 -control measureFlight suspension between HK and Wuhan Boarder restriction for non-HK residents with travel history to HubeiJanuary 30 -control measureClose 6 border-control pointsFebruary 4 -control measureClose 4 additional border-control pointsFebruary 9 -control measureQuarantine for all individuals coming from mainland China

We note that the sustaining enforcement in timely detection and other effective control measures are recommended in response to reduce the risk associated with SARS-CoV-2.
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